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CObjective: To explore the feasibility and potential role of the expected
value of individualized care (EVIC) framework. Methods: The EVIC
quantifies howmuch benefits are forgonewhen a treatment decision is
based on the best-expected outcomes in the population rather than in
the individual patient. We have reviewed which types of patient-level
attributes contribute to the EVIC and how they affect the interpretation
of the outcomes. In addition, we have applied the EVIC framework to
the outcomes of a microsimulation-based cost-effectiveness analysis
for glaucoma treatment. Results: For EVIC outcomes to inform deci-
sions about clinical practice, we need to calculate the parameter-spe-
cific EVIC of known or knowable patient-level attributes and compare it
with the real costs of implementing individualized care. In the case
study, the total EVIC was €580 per patient, but patient-level attributes
known at treatment decision had minimal impact. A subgroup policy O
o rep
olicy
al So
doi:10.1016/j.jval.2011.07.015ased on individual disease progression could be worthwhile if a pre-
ictive test for glaucoma progression could be developed and imple-
ented for less than €130 per patient. Conclusions: The EVIC frame-
ork is feasible in cost-effectiveness analyses and can be informative
or decision making. The EVIC outcomes are particularly informative
hen they are (close to) zero. When the EVIC has a high value, impli-
ations depend on the type of patient-level attribute. EVIC can be a
seful tool to identify opportunities to improve efficiency in health care
y individualization of care and to quantify the maximal investment
pportunities for implementing subgroup policy.
eywords: expected value of individualized care, glaucoma, heteroge-
eity, personalized medicine, value of information
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Decisions about the use of health-care technologies aremade on a
daily basis, both in a policy setting concerning the adoption of a
technology for a population in general and in the clinical setting
concerning treatment choices for individual patients. Such deci-
sions are often complex and made in the context of uncertainty.
Scientific decision analysis that employs amodel representing the
care system and patients of interest can inform such decisions. It
enables a rational and objective assessment of the options and
provides insight in the probability that they are optimal. There-
fore, decision analysis provides a tool to handle the existence of
uncertainty, but it does not negate it. Indeed, the outcomes ofmed-
ical decision analyses are surrounded by uncertainty of two main
types. The first is thatwe do not have a precise estimate of themean
expected outcomes in the population [1]. The second is that patients
are unique and therefore differ in expected outcomes [2].
Uncertainty surrounding the mean expected outcomes in the
population has relevance for decisions that are made on a popu-
lation level, such as which strategy should be the standard ap-
proach and which treatment should be reimbursed. Arguments
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1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.have beenmade that societal decisionmaking should be based on
the expected outcomes of economic analyses, not on their statis-
tical significance [3]. Exploration of uncertainty, however, can play
an important role in adoption decisions and provide valuable in-
formation for decisions regarding future research [4,5]. Several
methods have been developed to assess the impact of various
types of uncertainty on the expected outcomes and to use the
outcomes of uncertainty analysis to prioritize future research [6,7].
One of these methods is the value of information analysis, which
integrates information on the probability of making the wrong
decision with its consequences in terms of health effects and re-
sources forgone [8,9]. Value of information analysis is applicable to
all uncertainty that can be expressed in probability distributions
and is often used to assess uncertainty in population parameters.
In the latter context, it is predominantly referred to as expected
value of perfect information (EVPI) analysis [10]. The EVPI repre-
sents the value that society is willing to pay to optimize decision
making at the population level and can inform decisions about
additional research to reduce population parameter uncertainty.
Even if we had absolute certainty about the mean expected
outcomes in the population, however, we still know that individ-
ort.
and Management, Erasmus University Rotterdam, P.O. Box 1738,
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14 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1ual patients differ from one another, and therefore have different
expected outcomes due to heterogeneity and variability [11]. Vari-
ability is the variation in outcomes that is the result of random-
ness, or “the random chance that patients with the same under-
lying parameters will experience a different outcome” [11].
Variability has also been defined in this context as stochastic un-
certainty [7]. Heterogeneity, on the other hand, relates to the vari-
ation in outcomes that can be explained by patient-level attri-
butes, for example, age, disease stage, and comorbidity [11].
Patient-level uncertainty (i.e., heterogeneity and variability) may
not affect population expected values and therefore not affect
population-level decision making, but knowledge of the impact of
heterogeneity could identify opportunities to improve health care
by adopting subgroup policies or making individual treatment de-
cisions. It is natural for health-care providers to acknowledge het-
erogeneity and aim for individualized care to optimize the welfare
of their patients. The growing attention for individualized care is
also reflected in formal decision analysis. For instance,models are
being developed to predict the effect of different cancer treatment
modalities on survival and side effects in individual patients,
based on the patient’s attributes [12].
In 2007, Basu and Meltzer [13] introduced a theoretical frame-
work for value of information analysis based on uncertainty about
cost-effectiveness outcomes in individual patients. They termed it
the expected value of individualized care (EVIC) framework and
argued that the EVIC represents the potential value that society is
willing to pay so that individually efficient decisions are made. In
their example, individualization was based on patients’ prefer-
ences, but they stated that themethodwould also be applicable to
other individual-level attributes that might affect the costs and/or
benefits of treatments [13]. Since the EVIC framework could be a
tool in the generation of decision support regarding individualized
care, this article aims to examine the feasibility of the EVIC frame-
work when patient-level attributes other than preferences are
considered and how this affects the interpretation of the EVIC. In
addition, we aimed to explore the potential role of EVIC in decision
making. The remainder of this article is organized in three sections.
The first section provides a theoretical consideration of the EVIC
framework and the interpretation of the outcomes, the second sec-
tion presents an empirical application of the framework, and the
final sectionprovidesadiscussionofpractical issuesweencountered
and suggests implications of the main findings of this article.
Methods
Conceptual framework of EVIC
Within the EVIC framework, two approaches to patient manage-
ment are compared [13]. The first is the population-based ap-
roach, in which all patients receive the same treatment: the one
hat is optimal for the population outcomes. The second is the
ndividualized approach, in which each patient receives the treat-
ent that leads to optimal outcomes in that individual patient.
e speak of individualized care when anymedical decision in the
are cycle depends on a patient-level attribute. This can be as
imple as a subgroup policy based on a single attribute (e.g., breast
ancer screening based on age) or as complex as a custom-made
reatment plan for an individual patient based on a multitude of
atient-level attributes such as treatment history, biomarker pro-
le, and risk factors.
The EVIC quantifies the benefits forgone when a population-
ased approach rather than an individualized approach is used.
he concept can be illustrated with the fictive results in Figure 1.
his figure shows the incremental cost-effectiveness of a hypo-
hetical treatment relative to no treatment in three individual pa-
ients. Each cross represents the incremental costs and effects (in
uality-adjusted life-years [QALYs]) of treatment in each individ- tual patient. The diamond represents the average incremental
cost-effectiveness ratio (ICER) in the population and indicates that
treatment is expected to increase average health at some addi-
tional costs. The average ICER is lower than themaximumamount
society is willing to pay for an extra QALY () and would therefore
ustify a population-based approach to “treat everybody.” The fig-
re, however, also shows that treatment is neither effective (pa-
ient 3) nor cost-effective (patients 2 and 3) in all patients, and an
ndividualized approach would render better overall outcomes.
Calculation of EVIC
The benefits forgonewith a population-based approachmay include
both costs and effects and are expressed in either monetary units
(net monetary benefit, NMB) or health units (net health benefit). In
the present article, we use the NMB statistic, which is calculated by
multiplying the health effects with the willingness-to-pay threshold
 and subtracting the costs. A treatment is cost-effective when the
ncremental net monetary benefit (INMB) is positive. In this article,
e use the prefix “i–” (as in iNMB) to indicate individual patient out-
omes rather than average population outcomes.
The EVIC is calculated as the average of the maximum net
enefits of the treatments in each patient minus the maximum of
he average net benefits of the treatments in all patients as de-
oted in Equation 1:
VIC

maxj iNMBj()p()dmaxj

iNMBj()p()d (1)
here j represents the treatment options,  is a vector of patient-
evel attributes that determine the NMBs from any treatment j,
nd p() is the joint distribution of  in the population [13].
The calculation of EVIC is analogous to the calculation of EVPI,
but there are important differences too (Table 1). Equation 1 can be
simplified to Mean{maxj iNMBj} maxj{Mean iNMBj} [14]. An ex-
mple of the calculation of EVIC based on fictive data for the pa-
ients in Figure 1 is listed in Table 2. Treatment results in the
ighest average iNMB per patient (€158,000), but the maximal
chievable average iNMB (€178,000) would be obtained if only pa-
ient 1 were treated. Individualization of the treatment decision
ould therefore render €20,000 per patient.
The results in the example show that it ismost efficient to treat
nly patient 1, not patients 2 and 3. It also shows that treatment is
eneficial for patient 1 while it harms patient 3. Treatment is ben-
ficial for patient 2, but this patientwould not receive treatment in
he individualized approach discussed above because of the rela-
Fig. 1 – Cost-effectiveness plane with incremental
outcomes of three individual patients () and the
population-based mean incremental cost-effectiveness
ratio () [5]. QALYs, quality-adjusted life-years. Adapted
from Basu and Meltzer [13].ively high costs. This is the consequence of optimizing the deci-
aram
15V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1sion with an efficiency goal, but it is questionable whether it is
ethical to withhold treatment for patient 2. For this reason, Basu
and Meltzer [13] introduced the “EVIC without cost internaliza-
Table 1 – Similarities and differences between EVIC and EV
Level
Captures the value of optimizing
treatment decision on the level
of the
Individual
Source Patient he
Source Magnitude depends on
differences between
Individual
Source Data generated by Patient-le
compar
Calculation Total
EVICMe
Calculation Parameter specific
EVICiEV
EVPPIiE
Foundation Many valu
exist wi
the opti
individu
value of
Interpretation The magnitude indicates the Maximal v
individu
Interpretation Total EVIC
unless i
Interpretation Parameter
in comb
the actu
individu
Relationship EVIC and
EVIC, no
EVIC, expected value of individualized care; EVPI, expected value of p
effectiveness ratio; iNMB, individual net monetary benefit; ; , vector of
patient-level attributes; j treatment options;  , vector of population p
Table 2 – Calculation of EVIC based on fictive outcomes da
No treatment
Costs (€) QALYs iNMB (€) Costs
Patient 1 1,000 5 149,000 4,00
Patient 2 1,000 5 149,000 31,00
Patient 3 1,000 5 149,000 31,00
Mean(iNMB) 149,000
Maxj{Mean(iNMB)}
Mean{Maxj(iNMB)}
EVIC €178,000  €158,000  €20,000
EVIC, expected value of individualized care; iNMB, individual net m
iINMB, individual incremental net monetary benefit.tion.” In this alternative approach, the optimal intervention for
each individual patient is the one that produces the maximum
expected health benefits. In the example, this would lead to the
EVIC EVPI
nt Population
eneity and variability Population parameter uncertainty
s Average population ICERs
ulation or individual
effectiveness research
Probabilistic sensitivity analysis of
population parameters
axjiNMBj
MaxjMeaniNMBj
EVPIMeanMaxjNMBj
MaxjMeanNMBj
(Meani[MeancMaxjiNMBj(ci)]
Meani[MaxjMeanciNMBj(ci)])
(Meani[MeancMaxjNMBj(ci)]
Meani[MaxjMeancNMBj(ci)])
a patient-level attribute
patient population, and
reatment decision for an
tient depends on the
attribute.
There is one true value for a
parameter in the population, and
the average optimal treatment
decision for the patient
population depends on the value
of that parameter.
of implementing
d care
Maximal value of performing
additional research into the
population parameter
e is not informative,
ro.
Total EVPI value is not informative,
unless it is zero.
ific EVIC is informative
on with information on
sts of implementing
d care.
EVPPI is informative in combination
with information on the actual
costs of additional research.
re not correlated. The value of EVPI does not predict the value of
e versa.
information; EVPPI, parameter-specific EVPI; ICER, incremental cost-
nt-level attributes; i , patient-level attribute of interest; c , remaining
eters; i , parameter of interest; c , remaining (uncertain) parameters.
patients 1, 2 and 3 in Figure 1.
Treatment iINMB in
population-based
approach (€)
Max iNMB in
individualized
care (€)QALYs iNMB (€)
8 236,000 87,000 236,000
5.5 134,000 15,000 149,000
4.5 104,000 45,000 149,000
158,000
158,000
178,000
ary benefit when   €30,000 per quality-adjusted life-year (QALY);PI.
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16 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1decision to treat patients 1 and 2 (not 3), and the EVICwithout cost
internalization would be €15,000 per patient (Table 3).
Calculation of EVIC requires data on the outcomes of each
treatment option in each individual patient, and so data from
most (randomized) clinical studies are not suitable for EVIC anal-
ysis as they divide the study population into separate study arms.
Patient data for EVIC analysis must therefore be retrieved from
studies with special designs and analyzing techniques that allow
for individualized comparative effectiveness research, or be gen-
erated in decision-analytic models based on individual patient
simulation [15,16].
Interpretation of EVIC
The EVIC quantifies the net benefit that can, in theory, be gained
bymaking individualized rather than population-based decisions.
It therefore indicates themaximal investment that can bemade to
implement individualized care. For individualized care to be
worthwhile, the actual costs of implementation need to be lower
than the EVIC. This may be easily achieved when the implemen-
tation costs are low (e.g., introducing a contraindication for certain
surgical procedures), but facilitating individualized care may also
come at considerable costs, for example, when it requires thor-
ough genetic testing. However, there are several issues that need
to be considered in the interpretation of the total EVIC.
EVIC arises as a consequence of variation in iINMB between
patients; if therewere no variation in outcomes, the EVICwould be
zero. Alternatively, however, the fact that iINMBs are different in
the population does not necessarily result in a positive (i.e., non-
zero) EVIC. The EVIC has a positive value only when there are
patients in the population who have iINMBs on one side of the
acceptability threshold, while the average population’s INMB is on
the other. In addition, the magnitude of the EVIC is determined by
the distance of those iINMBs to the threshold line; the larger the
distance, the higher the EVIC.
Consider for example Figure 1. With a willingness-to-pay
threshold of €30,000 per QALY, only patients 2 and 3 “contribute”
to the total EVIC, which would be €20,000 per patient. At a thresh-
old of €10,000 per QALY, the population’s ICER would be above the
threshold line, and only patient 1 would contribute to the total
EVIC, which would be €9000. At a threshold of €0 per QALY, all
individual outcomes would be on the same side as the population
average (above threshold), and the EVIC would be €0.
When the EVIC has a positive value, there may be value in
individualizing care. The absolutemagnitude of the total EVIC rep-
resents the profit of giving each individual patient the optimal
treatment. In other words, the EVIC expressed as monetary units
per patient quantifies howmuch we canmaximally spend on per-
forming a “magic test” that would give us complete information
(i.e., reduce all uncertainty) about the outcome of treatment in an
individual patient. This theoretical interpretation is not very use-
ful in practice though. First, the value of the total EVIC does not
Table 3 – Calculation of EVIC without cost internalization bas
No treatment
Costs (€) QALYs iNMB
Patient 1 1,000 5 149,0
Patient 2 1,000 5 149,0
Patient 3 1,000 5 149,0
Mean(effect) 5
Most effective {Mean(iNMB)}
Mean{Most effective(iNMB)}
EVIC
EVIC, expected value of individualized care; iNMB, individual net monecessarily account for all relevant patient heterogeneity and vari-ability, particularly when the patient data are generated by an
individual patient simulation model. In the latter case, the EVIC
only represents the variability and patient heterogeneity that was
built into the model. Second, the interpretation as stated above
assumes that the “magic test” is readily available. In reality, the
testmay still need to be developed, which also costsmoney. Third,
it is unlikely that one test will be able to reduce all uncertainty. It is
more realistic that there will be a series of tests for separate pa-
tient-level attributes that together reduce part of the uncertainty.
Whether it is worthwhile to pursue this reduction in uncertainty
depends on the value of that reduction and the costs of developing
and performing these tests, which can be investigated with the pa-
rameter-specific EVIC calculations discussed below [13]. When the
total EVIC per patient is already very low, that is, lower than the cost
of any available or conceivable test, then there is no need to proceed
to parameter-specific EVIC calculations. In that case, the low EVIC
does not justify further efforts to individualize care.
Calculation of parameter-specific EVIC
The magnitude of the total EVIC may be impacted by many differ-
ent patient-level attributes. Some attributes may contribute more
than others and are therefore more interesting to explore for indi-
vidualized care. In addition, some attributes may bemore feasible
for the implementation of individualized care than are others (see
below). Their impact can be assessed and quantified with the pa-
rameter-specific EVIC, which represents the average benefits that
may be gained by choosing the optimal treatment for each indi-
vidual patient based on the value of that particular attribute (e.g.,
severity of disease) rather than a population-based approach. The
parameter-specific EVIC is calculated as the difference between
the total EVIC in the population-based approach and the EVIC that
remainswhen treatment is individualized to the attribute of inter-
est, as formulated in Equation 2:
EVICiEVIC 
xi
pi(x)EVIC(ci x) dx (2)
where i is the specific attribute of interest among the vector of
ttributes , c are the remaining attributes, and pi(x) is the mar-
ginal probability distribution of the attribute of interest [13]. Equa-
tion 2 can be simplified to
EVICiEVIC MeaniMeancMaxjiNMBj(ci)
MeaniMaxjMeanciNMBj(ci))
The parameter-specific EVIC is calculated from a series of simula-
tions consisting of inner loops and outer loops. In each inner loop,
a cohort of heterogeneous patients is simulated with a fixed value
for patient-level attribute i. All other attributes (c) are randomly
drawn for each individual patient. In each outer loop, a new value
n fictive outcomes data for patients 1, 2 and 3 in Figure 1.
Treatment iNMB of most
effective option (€)
Costs (€) QALYs iNMB (€)
4,000 8 236,000 236,000
31,000 5.5 134,000 134,000
31,000 4.5 104,000 149,000
6
158,000
173,000
173,000  €158,000  €15,000
y benefit when   €30,000 per quality-adjusted life-year (QALY).ed o
(€)
00
00
00
€for i is drawn from pi(x). Parameter-specific EVIC calculations can
12
3
17V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1be quite time-consuming. Therefore, it might be prudent to per-
form some exploratory analyses with the base case cohort data
(e.g., AN(C)OVA or stratified EVIC calculation [see supplemental
material at doi 10.1016/j.jval.2011.07.015]) to identify the most in-
fluential patient-level attributes, and perform parameter-specific
EVIC calculations on the most meaningful attributes only.
Interpretation of parameter-specific EVIC
For the interpretation of the parameter-specific EVIC it is impor-
tant to consider the nature of the patient-level attribute that is
targeted. Therefore, it may be helpful to distinguish the following
categories [2].
. Patient-level attributes known when the treatment decision is
made. These are attributes that are readily known or easily
measured, such as age, weight, and blood pressure. The param-
eter-specific EVIC of an attribute with a value known at the
treatment decisions suggests that the efficiency of care can be
improved if treatment decisions are based on this attribute.
Because the value of the attribute is readily known, there is no
need to allocate resources to retrieve its value with additional
testing. However, the actual implementation of an individual-
ized care policy may require extra investments such as equip-
ment to provide different types of care, extra housing and
(training of) staff, or the development and diffusion of clinical
guidelines. The parameter-specific EVIC therefore quantifies
the maximum investment that can be made to implement in-
dividualized care (Table 4).
. Patient-level attributes not known but measurable when the
treatment decision is made. These are attributes that are gen-
erally not readily known because they are not normally col-
lected in everyday patient care, for example, because of patient
discomfort or high costs, but that could be retrieved by per-
forming additional measurements. For example, when cancer
turns out to be irresectable during surgery, the unnecessary
operation may have been avoided if the irresectability of the
tumor had been diagnosed with more extensive imaging. Pa-
rameter-specific EVIC analysis could indicate whether routine
application of extended imaging would be worthwhile. Other
examples include genetic tests, invasive diagnostic tests, or
preference elicitation tests. The value of the parameter-specific
EVIC of an attribute that is not readily known quantifies the
maximum investment that can be made to implement individ-
ualized care. The maximum investment not only includes the
potential costs of implementing the individualized care policy
but also the costs of retrieving the unknown attribute (Table 4).
. Patient-level attributes revealed over time. These are attributes
that can be established in retrospect but that are neither known
normeasurable at themoment the treatment decision ismade.
For example, a patient’s response to medication in terms of
effects or side effects may be very important for the outcome of
Table 4 – Activities that can be financed within the limits o
parameter.
Type of parameter Provide
individualized
care
Heterogeneity
Known patient-level attribute x
Knowable patient-level attribute x
Patient-level attribute revealed over time x
Unexplained variability xEVIC, expected value of individualized care.treatment, but it is impossible to tell in advance what the re-
sponse will be. The parameter-specific EVIC of attributes that
are revealed over time indicates how much net benefits could
be gained if treatment decisions could be based on knowledge
that can be obtained only further down the road. Because it is
impossible to look into the future, these potential efficiency
gains are unlikely to be effectuated, unless 1) its value can be
evaluated in a short period of time or 2) there is another attri-
bute that predicts its value. In the first case, a treatment strat-
egy might be devised that involves postponement of the treat-
ment decision until the value is known, or “stopping rules” that
dictate abortion of a treatment strategy. In the second case,
individualized care may be based on the predicting attribute.
Take for example the case of duration of life versus life expec-
tancy: the former is a retrospective outcome while the latter is a
prospective predictor. Duration of life is likely to affect the out-
comes of treatment in individual patients, but it can be deter-
mined only at the end of a patient’s life. In this case, life expec-
tancy based on age, gender, and comorbiditiesmight be a suitable
predictor.When there is no readily available knowledge regarding
predictive attributes, a high parameter-specific EVICmay suggest
that there is value in additional research to obtain such knowl-
edge. The maximal investment, however, that can be made for
additional research is not equal to the parameter-specific EVIC,
because some financial room may need to be reserved for the
implementation of individualized care (Table 4).
In addition, differences in individual patient outcomesmay arise
not only from patient heterogeneity but also from variability. Vari-
ability may therefore have a nonzero parameter-specific EVIC, but
this number does not have practical relevance. It represents the in-
evitable loss of efficiency in health care as a result of coincidence. If
EVIC and parameter-specific EVIC have been calculated on the basis
of actual patient data rather than a simulation model, part of what
appears to be unexplained variability in statistical analyses may ac-
tually be attributable to (yet) unknown patient heterogeneity. A high
parameter-specific EVIC for unexplained variability may therefore
suggest that there is value in additional research in theory. This
would uncover such unknown sources of patient heterogeneity. It
may be, however, difficult, if not impossible, to calculate the maxi-
mal room for investment for such research from the EVIC.
Application of the EVIC framework to the case of glaucoma
To test the feasibility of the EVIC framework we have applied it to
the empirical data of a cost-effectiveness analysis for the treat-
ment of glaucoma. Primary open-angle glaucoma is a neurodegen-
erative disease of the optic nerve that can ultimately lead to loss of
peripheral vision and blindness [17]. Details of the analysis meth-
ods are provided in supplemental material to this article found at
doi 10.1016/j.jval.2011.07.015. Briefly, the cost-effectiveness data
had a lifelong horizon and a societal perspective and were gener-
parameter-specific EVIC, depending on the type of
trieve
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18 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1ated with a discrete event simulation model of individual glau-
coma patients. The construction and validation of themodel have
been reported elsewhere [18]. We quantified the severity of glau-
oma by the mean deviation (MD). A decrease in MD indicated
rogression (i.e., worsening) of glaucoma. In the model, each pa-
ient was assigned an initial MD (decibels) and an intrinsic rate of
rogression (decibels per month). We have compared the life-long
utcomes in terms of societal costs and QALYs in two treatment
trategies: high intensity versus low intensity (see supplemental
aterial at doi 10.1016/j.jval.2011.07.015). We generated a hetero-
eneous cohort of 3000 patients and simulated their disease pro-
ression in each of the two treatment strategies.We calculated the
VIC from the outcomes of the individual patients in both strate-
ies. In addition, we investigated the impact of population param-
ter uncertainty with a probabilistic sensitivity analysis and EVPI
alculation [6]. In calculations of NMB, EVPI, and EVIC, we have
sed an arbitrary  of €30,000 per QALY for illustrative purposes
19]. The (parameter-specific) EVICwascalculatedaccording toEqua-
ions 1 and 2 with cost internalization, unless stated otherwise. The
alculation of the parameter-specific EVIC was based on data from a
wo-level simulation. First, we sampled a value for the patient-level
ttribute of interest. Then, we simulated a cohort of 3000 patients in
hich each patient had a unique set of patient-level attributes, ex-
ept for the attribute of interest, which was fixed to the sampled
alue. This processwas repeatedwith newvalues for the attribute of
nterest until we observed a stable estimate for the parameter-spe-
ific EVIC. This was the case after 120 repetitions.
Results
Cost-effectiveness and EVIC
High-intensity treatment resulted in an average health gain of 0.12
QALYs and cost savings of €1527 per patient compared with low-
intensity treatment and was therefore the dominant strategy at
the population level. High-intensity treatment was more expen-
sive in terms of visits, medication, and surgery, but this was com-
pensated by cost savings in low-vision–related care.
Figure 2A visualizes the uncertainty in the population out-
comes due to parameter uncertainty through the results of the
probabilistic sensitivity analysis of parameter uncertainty. Figure
2B shows the population-level cost-effectiveness acceptability
Figure 2 – Cost-effectiveness of high-intensity treatment ver
Individual ICER (iICER) in each simulated patient (light gray)
ICERs from the probabilistic sensitivity analyses of paramet
curve (CEAC) (solid line) including EVPI per patient (dotted li
(solid line), indicating the percentage of patients in the popu
line). ICER, incremental cost-effectiveness ratio; EVIC, expec
information; QALY, quality-adjusted life-year; WTP, willingnesscurves. The EVPIwas €0, indicating that there is no value in further
research to improve decision making at the population level.
In Figure 2A we have also drawn the scatter of ICER outcomes
(iICERs) of the individual patients in the simulated cohort. It shows
that the uncertainty at the individual level due to patient hetero-
geneity and variability was much larger than the uncertainty at
the population level due to parameter uncertainty. Each light gray
dot in Figure 2A represents the incremental costs and effects of
high-intensity treatment compared with low-intensity treatment
in one individual patient in the simulated cohort. High-intensity
treatmentwasmore effective than low-intensity treatment in 91%
of the patients, and the percentage of patients with an acceptable
ICER was 68% (Figure 2C). The EVIC was €580 per patient, suggest-
ing that there is room for improvement in the efficiency of care by
taking into account the expected outcomes of a patient in an in-
dividual treatment decision. The value of the EVIC without cost
internalization was €189.
Parameter-specific EVIC
In an analysis of (co)variance including all simulated patient-level
attributes, 41% of all observed variance was explained. The pro-
portion of the total sum of squares explained by each of the attri-
butes is drawn in Figure 3. The first seven attributes are known at
the moment the treatment decision is made, and the remaining
attributes are revealed over time. The attributes known at treat-
ment decision appeared to have a minimal contribution to the
variability in individual cost-effectiveness outcomes. As a conse-
quence, it cannot be expected that EVIC can be reduced by indi-
vidualizing care based on any of these attributes, and therefore
there is no opportunity to improve efficiency in care on the basis of
readily available information about the patients.
Two attributes stand out in Figure 3: duration of life and pro-
gression rate. Duration of life is a patient-level attribute that is
revealed when a patient dies and that can therefore never play a
role in treatment decisions. In clinical practice, life expectancy
based on gender, age, and health state could be a good predictor
for duration of life and therefore be a candidate attribute for indi-
vidualized care. In the model outcomes, however, life expectancy
had only aminor impact whenwe entered it instead of duration of
life into the ANCOVA. The other attribute, progression rate, is in
reality also revealed over time. However, for the sake of illustra-
tion let us hypothesize that its valuemay be predictablewith a test
low-intensity treatment in glaucoma patients. A:
average ICER in the population (black), and the population
certainty (dark gray). B: Cost-effectiveness acceptability
C: Individual cost-effectiveness acceptability curve (iCEAC)
n with a positive iINMB, and the EVIC per patient (dotted
alue of individualized care; EVPI, expected value of perfectsus
, the
er un
ne).
latio
ted vto pay.
19V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1that is yet to be developed. The parameter-specific EVIC of pro-
gression rate would indicate the value of that test, and therefore
inform us whether it would be feasible to develop and implement
it in clinical practice. The value of this parameter-specific EVIC for
progression rate was €130. This indicates that it would be worth-
while to spend €130 per patient to implement a subgroup policy
based on progression rate. The maximum investment to develop
the measurement instrument may be aggregated over all patients
to whom the treatment decision will apply. For example, with an
annual number of new glaucoma patients of 10,000, and an as-
sumed applicability period of 10 years, the total number is 100,000
patients [20]. This indicates that the maximum investment for
development and implementation of a 100% sensitive and specific
progression prediction test is €13 million.
Suppose that the above-mentioned figures give rise to a posi-
tive decision regarding a subgroup treatment policy, the next
question would be how treatment decisions should be adjusted to
individual progression rates. A solution can be found in the results
from the parameter-specific EVIC simulations. If the rate of pro-
gression has an impact on the cost-effectiveness of glaucoma
treatment, there should be a turning-point value for progression
rate at which the preferred strategy switches from low-intensity
treatment to high-intensity treatment. In Figure 4 we have plotted
the fixed value for the progression rate in each of the outer loops
from the parameter-specific EVIC simulations against the average
INMB of high-intensity treatment compared with low-intensity
treatment found in that particular patient population. Up to pro-
gression rates of 0.008 dB/mo, the average INMB of intensive treat-
ment was negative, which implies that low-intensity treatment is
most efficient. At MD progression rate values higher than 0.008
dB/mo, the INMB of intensive treatment was positive, which im-
plies that high-intensity treatment is most efficient. Therefore,
individualized care could consist of low-intensity treatment in pa-
tients with an MD progression rate of lower than 0.008 dB/mo and
Fig. 3 – Proportion of the total sum of squares explained by
Med, medicine; IOP, intraocular pressure.high-intensity treatment in everyone else.Discussion
In this articlewehave explored the EVIC framework and applied it to
a real-world example to assess the feasibility and potential role of
EVIC analysis in decisionmaking. The importance of patient hetero-
geneity is increasingly recognized inmedical research and acknowl-
edged in clinical practice, because it offers the opportunity to tailor
medical decisions to the individual attributes of the patient. Previ-
ously, Hoch et al. [21] have described the application of regression-
based analysis techniques to investigate the impact of patient heter-
ogeneity on cost-effectiveness outcomes in a patient population and
to identify the most influential patient-level attributes. A strong re-
lationship between a patient-level attribute and treatment out-
comes, however, is not enough argument to pursue individualized
care. The key advantage of the EVIC framework is that it puts amax-
imum value to the efforts to individualize care, which, in combina-
tion with knowledge about the costs of those efforts, enables us to
judge whether individualized care is likely to be worthwhile.
In this exploration of the EVIC framework we encountered a
number of methodological issues. First, because the derivation of
the parameter-specific EVIC is similar to that of the partial EVPI,
and because several methods have been described to calculate
partial EVPI, it is likely that there are other (mathematically equiv-
alent) methods to calculate the parameter-specific EVIC than the
one we have followed [14]. However, partial EVPI calculations
based on the reduction in expected opportunity loss may lead to
biased estimates [10]. Whether this also applies to parameter-spe-
cific EVIC calculations as proposed by Basu andMeltzer remains to
be resolved and is a question that was outside the scope of the
research in this article. Second, the calculation of parameter-spe-
cific EVIC can be quite time-consuming. Generating data for a sin-
gle cohort of patients in an individual patient sampling model
requires many simulations. The simulation of inner and outer
loops for each patient-level attribute of interest can add up con-
tient-level attributes in the model. MD, mean deviation;all pasiderably, and so it may be worthwhile to consider methods to
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20 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1increase the efficiency of the analyses. These methods may in-
clude the grouping of attributes of interest into an aggregate pa-
rameter-specific EVIC calculation using a one-level algorithm, or
use of a meta-model [22]. Third, in the empirical example in this
rticle we have used ANCOVA as a screening tool to select poten-
ial attributes of interest and limit the number of parameter-spe-
ific analyses. ANCOVA assumes a linear relationship between the
arameters and the INMB, but linearity may be violated or inter-
ctions may play a role. This could be the reason why only 41% of
ll variance was explained in the example. If there are clear indi-
ations of nonlinearity in the data, it may be better to use nonlin-
ar statistical models. Fourth, a simulationmodel canmimic real-
ife variability in outcomes by employing random draws. When a
ingle patient is simulated in different treatment strategies, the
andom draws in each strategy may not be similar. As a result, a
imulated patient with a high risk of event X in the comparator
trategy may remain event-free as a result of favorable random
raws, while the same patient with a low risk of event X in the
lternative strategymay experience it because of unfavorable ran-
om draws. It is questionable whether that impact is valid in this
ase, because it was not the result of an increased risk of event X.
he occurrence of the event in only one of the scenarios could
ncrease the magnitude of the individual incremental outcomes,
hich could, in turn, contribute to themagnitude of the EVIC; this
odel-induced variability could therefore create noise in the EVIC
utcomes. We tested this with the glaucoma model, which by de-
ault used similar random draw values in both treatment strate-
ies. Because of dissimilar random draws, the total EVIC grew
rom €580 to €881. The parameter-specific EVIC of progression rate,
however, was €117, which is comparable to the €130 found earlier.
herefore, it seems that although model-induced variability can
ause an artificially high value for total EVIC, it may not affect the
alues of the parameter-specific EVIC. Lastly, the validity of EVIC is
onditional upon the validity of all assumptions associated with
ost-effectiveness analysis and the INMB framework, such as the
alidity of using utility estimates, the validity of the model struc-
ure, the assumption thatwe know the value of , and the assump-
ion that willingness to pay is equal to willingness to accept [23–
6]. The value of EVIC is highly dependent on , not only in terms
of its absolute value but also in terms of the relative impact of the
heterogeneous attributes. A different value of  could thus impact
Fig. 4 – Results from the simulations for the parameter-spec
the fixed MD progression rate in the population against the
treatment versus low-intensity treatment in that population
EVIC, expected value of individualized care; INMB, incrementhe implications of the EVIC outcome [25]. zThere is a great deal of analogy between the EVPI and the EVIC
framework (Table 1). Indeed, the impressive amount of work con-
ducted to date on the development of the EVPI framework could
greatly benefit the dissemination of the EVIC methodology. It is
important, however, to realize that both frameworks represent
two essentially different concepts, and both analyses may be per-
formed in cost-effectiveness research; they are complementary.
The foundation of EVPI is that there is one true value for a param-
eter in the population and that the optimal treatment decision for
all patients in the population depends on the value of that param-
eter. With additional research we could remove all uncertainty,
and so we would know the parameter value and could therefore
make the optimal treatment decision on a population level. Alter-
natively, the foundation of EVIC is that many values for a patient-
level attribute exist within a patient population and that the opti-
mal treatment decision for an individual patient depends on the
value of that attribute. The EVIC represents the value of acquiring
and acknowledging all relevant patient-level information in the
treatment decision for an individual patient.
The aim of this article was to explore the potential role of the
EVIC framework in cost-effectiveness analysis and decision mak-
ing. Basu and Meltzer [13] stated that “EVIC can provide a guide as
to when population-level decision making may be especially at
risk of providing poor guidance for coverage decisions because of
failure to account for the value of individualized decisionmaking.”
On the basis of exploration of the EVIC framework described in
this article, we would argue that the reverse is true and that the
EVIC can provide a guide as to when population-level decision
making is not at risk of providing poor guidance, both for medical
nd for policy decisions. This statement is based on the finding
hat the outcomes of EVIC and parameter-specific EVIC calcula-
ions are most conclusive when they are zero. In addition, the
utcomes of parameter-specific EVIC calculations are informative
hen the parameter in question relates to a patient-level attribute
hose value is known or measurable at the time the treatment
ecision is made. From a policy perspective, this translates to a
otential role for EVIC to confirm that an adoption decision can be
ade on a population level, or provide a basis for a partial adop-
ion decision (i.e., implement a subgroup policy) on the basis of a
easurable patient-level attribute. As policies are generally made
o seek an efficient allocation of existing resources and a maximi-
VIC of MD progression rate. The graph plots the value of
age incremental monetary net benefit of high-intensity
ck) and the EVIC in that population (gray). DB, decibel;
et monetary benefit; MD, mean deviation.ific E
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21V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 3 – 2 1plicitly considered in the policy context. The EVIC calculationwith
cost internalization is therefore likely the most suitable approach
for the policy perspective. Decisions regarding the allocation of
resources to additional research may also be in the domain of the
policy maker. On the basis of the findings in this article, however,
we would conclude that results from EVIC analyses are informa-
tive regarding additional research only when they are zero and
therefore indicate that there is no value in additional research.
For the perspective of a clinical decisionmaker, that is, health-
care providers or health-care organizations, roughly the same
conclusions regarding the potential role of EVIC can be drawn.
From the clinical perspective, the EVIC outcomes may be most
relevant when they are calculated without cost internalization.
The potential role for EVIC analysis without cost internalization is
most evident when the outcome is zero, because it indicates that
there is low risk of poor guidance from population-level decision
making, for example, in the context of treatment guidelines. In
addition, parameter-specific outcomes of known or measurable
patient-level attributes can indicate whether it is worthwhile to
implement individualized care in clinical practice.
Conclusion
Building on the EVIC framework developed by Basu andMeltzer in
the context of heterogeneity in patient preferences, we have illus-
trated that it is feasible to apply the EVIC framework to all other
patient-level attributes thatmay affect the costs and/or benefits of
treatment. EVIC can be a useful tool to identify opportunities to im-
prove efficiency in health care by individualization of care and to
quantify the maximal investment opportunities for implementing
subgroup policy. The EVIC outcomes can play a role in both policy
and clinical decision making, particularly when they are zero or
when they concern known or measurable patient attributes.
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